Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
TransCode Therapeutics, Inc. (RNAZ)
USD8.70
+0.12 (+1.34%)
US NASDAQ Healthcare Biotechnology
Address
6 Liberty Square 2109
Boston, MA, US
Boston, MA, US
CEO
Philippe Calais
Website
transcodetherapeutics.com
IPO
2021-07-08
CIK 1829635 ISIN US89357L5012
Description
TransCode Therapeutics, Inc. is a biopharmaceutical firm dedicated to pioneering and marketing therapeutic agents and diagnostic tools specifically aimed at combating and detecting metastatic disease. Central to its pipeline is TTX-MC138, a lead therapeutic compound currently undergoing preclinical evaluation for its potential in treating advanced, spreading cancers. Beyond its primary candidate, the company's preclinical portfolio also features TTX-siPDL1, an siRNA designed to modulate programmed death-ligand 1, and TTX-siLIN28B, another siRNA that inhibits the RNA-binding protein LIN28B. TransCode also pursues several cancer-agnostic initiatives. These encompass TTX-RIGA, an RNA-based agent engineered to stimulate the RIG-I immune pathway within the tumor's immediate surroundings; TTX-CRISPR, a gene-editing platform utilizing CRISPR/Cas9 technology to correct or eradicate oncogenic genes within cancer cells; and TTX-mRNA, an innovative mRNA platform dedicated to creating cancer vaccines that incite powerful cytotoxic immune reactions against malignant cells. Established in 2016, TransCode Therapeutics is headquartered in Boston, Massachusetts.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD8.70
+0.12 (+1.34%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
54.4K
Beta
1.29
Float Shares
833.7K
Free Float %
90.9%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -2.78% | -7.30% | -25.00% | -23.79% | -29.86% | -3.37% | -1.49% | -100.00% | -100.00% | -100.00% | -100.00% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (1 ratings, all time)
Buy
Price Targets & DCF
Current price
8.70
DCF (Unlevered)
30.08
+245.9%
DCF (Levered)
25.83
+197.0%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2025-07 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
0.09
Distress
Piotroski F-Score
1 / 9
Weak
MOAT Score
3 / 10
No MOAT
Composite Rating
B-
Overall Score
2 / 5
Medium
DCF Score
5 / 5
High
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
5 / 5
High
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%-11.6% Q1'26: -30,174.6% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%— Q1'26: +0.2% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+93.7% Q1'26: +432.3% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×0.00× Q1'26: 0.00× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
Dec 2029 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|
| Revenue |
—
est: 300.0K (-100.0%)
|
—
est: 1.00M (-100.0%)
|
500.0K
500.0K – 500.0K
-50.0% YoY
|
9.70M
9.70M – 9.70M
+1,840.0% YoY
|
9.90M
9.90M – 9.90M
+2.1% YoY
|
27.80M
27.80M – 27.80M
+180.8% YoY
|
| EBITDA |
-16.19M
|
-34.31M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EBIT |
-16.73M
|
-34.43M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| Net Income |
-16.75M
est: -3.03B (+99.4%)
|
-34.66M
est: -31.48M (-10.1%)
|
-6.18M
-6.18M – -6.18M
+80.4% YoY
|
-4.63M
-4.63M – -4.63M
+25.0% YoY
|
-3.86M
-3.86M – -3.86M
+16.7% YoY
|
-3.48M
-3.48M – -3.48M
+10.0% YoY
|
| SGA |
5.51M
|
5.77M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EPS |
-47.14
est: -4,398.24 (+98.9%)
|
-52.59
est: -45.64 (-15.2%)
|
-8.96
-8.96 – -8.96
+80.4% YoY
|
-6.72
-6.72 – -6.72
+25.0% YoY
|
-5.60
-5.60 – -5.60
+16.7% YoY
|
-5.04
-5.04 – -5.04
+10.0% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-15 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-14 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-13 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-12 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-11 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-08 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-07 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-06 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-05 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-04 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-01 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-30 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-29 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-28 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-27 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-24 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-23 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-22 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-21 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-20 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-17 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-16 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
Owner Earnings
Owner's Earnings (history)
Owner's Earnings history not available.
Owner alignment
Owner's Earnings TTM
—
OE per share TTM
—
Owner's Yield
—
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
—
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
5
Total invested
154.0K
Insider transactions (90d)
0
Beneficial owners (>5%)
11
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Jeff Easton | 2.50M | 9.90% | 2.50M | — | 2.50M | — | IN | Delaware | 2023-12-07 | ↗ |
| 2 | Lind Global Fund II LP | 2.50M | 9.90% | 2.50M | — | 2.50M | — | PN | Delaware | 2023-12-07 | ↗ |
| 3 | Lind Global Partners II LLC | 2.50M | 9.90% | 2.50M | — | 2.50M | — | OO | Delaware | 2023-12-07 | ↗ |
| 4 | Robert Michael Dudley | 1.76M | 12.70% | 1.76M | — | 1.76M | — | IN | United States of America | 2022-12-20 | ↗ |
| 5 | LP | 1.72M | 9.90% | — | 1.72M | — | 1.72M | PN | Delaware, United States | 2024-07-26 | ↗ |
| 6 | Maier Joshua Tarlow | 1.72M | 9.90% | — | 1.72M | — | 1.72M | IN | Delaware, United States | 2024-07-26 | ↗ |
| 7 | Management LLC | 1.72M | 9.90% | — | 1.72M | — | 1.72M | OO | Delaware, United States | 2024-07-26 | ↗ |
| 8 | Zdravka Medarova | 1.62M | 12.50% | 1.62M | — | 1.62M | — | IN | United States of America | 2022-12-20 | ↗ |
| 9 | (. | 1.27M | 9.90% | 1.27M | — | 1.27M | — | IN | Maryland | 2021-07-21 | ↗ |
| 10 | 27-4413262 | 1.27M | 9.90% | 1.27M | — | 1.27M | — | OO | Maryland | 2021-07-21 | ↗ |
| 11 | Thomas A. Fitzgerald | 422.0K | 5.50% | 422.0K | — | 422.0K | — | IN | United States of America | 2024-06-21 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
5
+0 vs prev Q
New positions
3
Closed positions
3
Increased
5
Reduced
0
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | GEODE CAPITAL MANAGEMENT, LLC | 12.7K +12.7K (+100.0%) | 109.7K +109.7K (+100.0%) | 1.39% +1.389 pp | 0.00% +0.000 pp | USD8.61 +0.0% | 1 qtrs NEW |
| 2 | UBS GROUP AG | 8.3K +5.3K (+179.9%) | 71.4K +51.2K (+252.8%) | 0.90% +0.475 pp | 0.00% +0.000 pp | USD7.97 +8.0% | 4 qtrs — |
| 3 | — | 6.5K +6.5K (+100.0%) | 56.4K +56.4K (+100.0%) | 0.71% +0.714 pp | 0.00% +0.000 pp | USD8.61 +0.0% | 1 qtrs NEW |
| 4 | VANGUARD FIDUCIARY TRUST CO | 3.0K +3.0K (+100.0%) | 25.7K +25.7K (+100.0%) | 0.33% +0.325 pp | 0.00% +0.000 pp | USD8.61 +0.0% | 1 qtrs NEW |
| 5 | TOWER RESEARCH CAPITAL LLC (TRC) | 228.00 -659.0 (-74.3%) | 2.0K -4.1K (-67.6%) | 0.02% -0.104 pp | 0.00% 0.000 pp | USD6.98 +23.4% | 4 qtrs — |
| 6 | WELLS FARGO & COMPANY/MN | 55.00 +55.0 (+100.0%) | 474.00 +474.0 (+100.0%) | 0.01% +0.006 pp | 0.00% +0.000 pp | USD8.60 +0.1% | 1 qtrs NEW |
| 7 | SBI SECURITIES CO., LTD. | 12.00 +2.0 (+20.0%) | 103.00 +35.0 (+51.5%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD7.92 +8.7% | 4 qtrs — |
| 8 | ADVISOR GROUP HOLDINGS, INC. | — -3.0 (-100.0%) | — -20.0 (-100.0%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD— | 4 qtrs SOLD |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 2 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Vanguard Extended Market ETF VXF | 0.00% | 32.9K | 0.05% |
| 2 | Vanguard Extended Market ETF VXF | 0.00% | 1.0K | 0.05% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
12
Sells
0
Shares acquired
1.26M
Shares disposed
—
Cash buys
4.00
Cash sales
—
Net activity
+1,255,107
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-12-19 | STOVER JACK E | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2025-10-06 | CZEREPAK ELIZABETH | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-06-14 | Marquet Magda | Director | A-Award | A | Stock Option (right to buy) | 70,000 | 1.20 | 84.0K | 70,000 | — | ↗ |
| 2024-06-14 | Manting Erik | Director | A-Award | A | Stock Option (right to buy) | 70,000 | 1.20 | 84.0K | 70,000 | — | ↗ |
| 2024-06-14 | Fitzgerald Thomas A | Director / Officer | A-Award | A | Stock Option (right to buy) | 650,000 | 1.20 | 780.0K | 650,000 | — | ↗ |
| 2024-06-14 | Calais Philippe | Director | A-Award | A | Stock Option (right to buy) | 70,000 | 1.20 | 84.0K | 70,000 | — | ↗ |
| 2023-09-28 | Fitzgerald Thomas A | Director / Officer | P-Purchase | A | Common Stock | 49,350 | 0.51 | 25.2K | 56,318 | — | ↗ |
| 2023-09-28 | Dudley Robert Michael | Director / Officer | P-Purchase | A | Common Stock | 98,000 | 0.51 | 50.0K | 180,262 | — | ↗ |
| 2023-06-21 | Dudley Robert Michael | Director / Officer | P-Purchase | A | Common Stock | 12,000 | 2.65 | 31.8K | 82,262 | — | ↗ |
| 2023-06-20 | Dudley Robert Michael | Director / Officer | P-Purchase | A | Common Stock | 6,607 | 2.55 | 16.8K | 70,262 | — | ↗ |
| 2023-06-09 | Dudley Robert Michael | Director / Officer | P-Purchase | A | Common Stock | 19,000 | 2.76 | 52.4K | 61,155 | — | ↗ |
| 2023-05-19 | Marquet Magda | Director | A-Award | A | Stock Option (right to buy) | 45,000 | 0.28 | 12.8K | 45,000 | — | ↗ |
| 2023-05-19 | Manting Erik | Director | A-Award | A | Stock Option (right to buy) | 45,000 | 0.28 | 12.8K | 45,000 | — | ↗ |
| 2023-05-19 | Fitzgerald Thomas A | Director / Officer | A-Award | A | Stock Option (right to buy) | 300,000 | 0.28 | 85.0K | 300,000 | — | ↗ |
| 2023-05-19 | Dudley Robert Michael | Director / Officer | A-Award | A | Stock Option (right to buy) | 735,000 | 0.28 | 208.3K | 735,000 | — | ↗ |
| 2023-05-19 | Calais Philippe | Director | A-Award | A | Stock Option (right to buy) | 45,000 | 0.28 | 12.8K | 45,000 | — | ↗ |
| 2023-05-10 | Marquet Magda | Director | A-Award | A | Stock Option (Right to Buy) | 9,500 | 0.30 | 2.8K | 9,500 | — | ↗ |
| 2023-05-10 | Manting Erik | Director | A-Award | A | Stock Option (Right to Buy) | 9,500 | 0.30 | 2.8K | 9,500 | — | ↗ |
| 2023-05-10 | Calais Philippe | Director | A-Award | A | Stock Option (Right to Buy) | 9,500 | 0.30 | 2.8K | 9,500 | — | ↗ |
| 2022-12-12 | Medarova Zdravka | Officer | A-Award | A | Stock Option (Right to Buy) | 60,000 | 0.00 | — | 60,000 | — | ↗ |
| 2022-12-12 | Fitzgerald Thomas A | Officer | A-Award | A | Stock Option (Right to Buy) | 100,000 | 0.00 | — | 100,000 | — | ↗ |
| 2022-12-12 | Dudley Robert Michael | Officer | A-Award | A | Stock Option (Right to Buy) | 135,000 | 0.00 | — | 135,000 | — | ↗ |
| 2022-09-14 | Dudley Robert Michael | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 20,000 | 1.15 | 23.0K | 893,114 | — | ↗ |
| 2022-06-22 | Marquet Magda | Director | A-Award | A | Stock Option (Right to Buy) | 9,500 | 1.24 | 11.8K | 9,500 | — | ↗ |
| 2022-06-22 | Manting Erik | Director | A-Award | A | Stock Option (Right to Buy) | 9,500 | 0.00 | — | 9,500 | — | ↗ |
| 2022-06-22 | Calais Philippe | Director | A-Award | A | Stock Option (Right to Buy) | 9,500 | 0.00 | — | 9,500 | — | ↗ |
| 2022-06-16 | Fitzgerald Thomas A | Officer | P-Purchase | A | Common Stock | 12,000 | 1.27 | 15.2K | 139,377 | — | ↗ |
| 2022-05-27 | Dudley Robert Michael | Officer | P-Purchase | A | Common Stock | 28,000 | 1.84 | 51.6K | 871,114 | — | ↗ |
| 2022-03-01 | Fitzgerald Thomas A | Officer | A-Award | A | Stock Option (Right to Buy) | 52,000 | 0.00 | — | 52,000 | — | ↗ |
| 2022-02-01 | Medarova Zdravka | Officer | A-Award | A | Stock Option (Right to Buy) | 33,000 | 0.00 | — | 33,000 | — | ↗ |
| 2022-02-01 | Fitzgerald Thomas A | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 33,000 | 2.45 | 80.9K | 33,000 | — | ↗ |
| 2022-02-01 | Dudley Robert Michael | Director / Officer / 10% Owner | A-Award | A | Stock Option (Right to Buy) | 135,000 | 2.45 | 330.8K | 135,000 | — | ↗ |
| 2021-07-08 | Marquet Magda | Director | — | D | Stock Option (Right to Buy) | 36,393 | 3.91 | 142.2K | 0 | — | ↗ |
| 2021-07-08 | Manting Erik | Director | — | D | Stock Option (Right to Buy) | 36,393 | 3.91 | 142.2K | 0 | — | ↗ |
| 2021-07-08 | Fitzgerald Thomas A | Director / Officer | — | D | Stock Option (Right to Buy) | 242,622 | 0.08 | 19.9K | 0 | — | ↗ |
| 2021-07-08 | Dudley Robert Michael | Director / Officer / 10% Owner | — | D | Stock Option (Right to Buy) | 818,852 | 0.09 | 74.5K | 0 | — | ↗ |
| 2021-07-08 | Calais Philippe | Director | — | D | Common Stock | 0 | 0.00 | — | 127,377 | — | ↗ |
Executive team
Top executives
Shares Outstanding
917.0K
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2024 | Thomas A. Fitzgerald Interim Chief Executive Officer, Vice President and Chief Financial Officer | 255.1K | — | — | 701.9K | — | — | 957.0K | 73.35% | ↗ |
| 2 | 2024 | Robert Michael Dudley Former Chief Executive Officer | 85.4K | — | — | — | — | — | 85.4K | 0.00% | ↗ |
| 3 | 2023 | Robert Michael Dudley Former Chief Executive Officer | 474.4K | — | — | 168.4K | — | — | 642.8K | 26.20% | ↗ |
| 4 | 2023 | Thomas A. Fitzgerald Interim Chief Executive Officer, Vice President and Chief Financial Officer | 358.1K | — | — | 68.7K | — | — | 426.9K | 16.10% | ↗ |
| 5 | 2022 | Robert Michael Dudley Former Chief Executive Officer | 494.0K | — | — | 311.0K | — | — | 805.0K | 38.64% | ↗ |
| 6 | 2022 | Robert Michael Dudley Chief Executive Officer | 494.0K | — | — | 311.0K | — | — | 805.0K | 38.64% | ↗ |
| 7 | 2022 | Thomas A. Fitzgerald Interim Chief Executive Officer, Vice President and Chief Financial Officer | 371.0K | — | — | 189.7K | — | — | 560.7K | 33.83% | ↗ |
| 8 | 2022 | Thomas A. Fitzgerald Vice President and Chief Financial Officer | 371.0K | — | — | 189.7K | — | — | 560.7K | 33.83% | ↗ |
| 9 | 2021 | Robert Michael Dudley Chief Executive Officer | 240.0K | 255.5K | — | — | — | — | 495.5K | 0.00% | ↗ |
| 10 | 2021 | Thomas A. Fitzgerald Vice President and Chief Financial Officer | 180.0K | 137.6K | — | — | — | — | 317.6K | 0.00% | ↗ |
| 11 | 2020 | Robert Michael Dudley Chief Executive Officer | — | — | — | 43.0K | — | — | 43.0K | 100.00% | ↗ |
| 12 | 2020 | Thomas A. Fitzgerald Vice President and Chief Financial Officer | — | — | — | 15.4K | — | — | 15.4K | 100.00% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
| Filing date | Form type | Filing |
|---|---|---|
| 2026-05-08 | PRE 14A | ↗ |
| 2026-04-07 | DEFA14A | ↗ |
| 2026-03-03 | DEFA14A | ↗ |
| 2025-12-23 | DEFA14A | ↗ |
| 2025-10-27 | DEFA14A | ↗ |
| 2025-10-17 | DEFA14A | ↗ |
| 2025-10-08 | DEFA14A | ↗ |
| 2025-10-08 | DEFA14A | ↗ |
| 2025-07-15 | DEF 14A | ↗ |
| 2025-04-21 | DEFA14A | ↗ |
| 2025-04-16 | DEFA14A | ↗ |
| 2025-04-11 | DEF 14A | ↗ |
| 2025-04-02 | PRE 14A | ↗ |
| 2025-02-04 | DEFA14A | ↗ |
| 2024-12-30 | DEF 14A | ↗ |
| 2024-12-19 | PRE 14A | ↗ |
| 2024-11-13 | DEFA14A | ↗ |
| 2024-11-06 | DEFA14A | ↗ |
| 2024-10-28 | DEF 14A | ↗ |
| 2024-10-15 | PRE 14A | ↗ |
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Thomas A. Fitzgerald | Chief Financial Officer, President, Vice President of Administration & Director | 1M | male |
| Philippe Calais | Chief Executive Officer & Executive Chairman of the Board | 566.1K | — |
| Anna Moore | Scientific Co-Founder, Scientific Advisor & Chair of Scientific Advisory Board | — | — |
| Daniel R. Vlock | Chief Medical Officer | — | — |
| Susan Duggan | Senior Vice President of Operations | — | female |
| Zdravka Medarova | Scientific Co-Founder & Chief Scientific Officer | — | — |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for RNAZ
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
